Chemours (NYSE:CC) Price Target Raised to $21.00

Chemours (NYSE:CC) had its target price upped by Mizuho from $17.00 to $21.00 in a report published on Thursday,Benzinga reports. They currently have an outperform rating on the specialty chemicals company’s stock.

CC has been the subject of a number of other research reports. BMO Capital Markets dropped their price objective on Chemours from $20.00 to $19.00 and set an “outperform” rating for the company in a report on Monday, February 23rd. Jefferies Financial Group reiterated a “hold” rating and set a $17.00 target price on shares of Chemours in a research report on Monday, February 23rd. UBS Group boosted their target price on shares of Chemours from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. Truist Financial raised their price target on shares of Chemours from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, January 21st. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Chemours in a report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Chemours currently has an average rating of “Hold” and a consensus target price of $18.40.

Chemours Stock Performance

Chemours stock opened at $16.44 on Thursday. The company has a debt-to-equity ratio of 16.33, a current ratio of 1.78 and a quick ratio of 0.85. The firm has a market capitalization of $2.47 billion, a P/E ratio of -6.63 and a beta of 1.60. Chemours has a 1-year low of $9.13 and a 1-year high of $21.85. The company’s 50-day moving average is $16.38 and its 200 day moving average is $14.74.

Chemours (NYSE:CC) last announced its earnings results on Thursday, February 19th. The specialty chemicals company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.04. Chemours had a positive return on equity of 41.75% and a negative net margin of 6.41%.The business had revenue of $1.33 billion during the quarter, compared to analyst estimates of $1.33 billion. During the same quarter in the previous year, the business earned $0.09 earnings per share. The company’s revenue for the quarter was down 2.2% compared to the same quarter last year. Research analysts forecast that Chemours will post 2.03 EPS for the current year.

Chemours Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 13th. Investors of record on Friday, February 27th will be issued a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Friday, February 27th. Chemours’s dividend payout ratio (DPR) is presently -14.11%.

Institutional Trading of Chemours

A number of hedge funds have recently bought and sold shares of CC. Oregon Public Employees Retirement Fund increased its holdings in shares of Chemours by 1.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 34,300 shares of the specialty chemicals company’s stock valued at $404,000 after acquiring an additional 600 shares during the period. Amalgamated Bank boosted its position in Chemours by 1.7% during the third quarter. Amalgamated Bank now owns 43,528 shares of the specialty chemicals company’s stock valued at $689,000 after purchasing an additional 740 shares in the last quarter. PFG Investments LLC grew its stake in Chemours by 7.6% in the fourth quarter. PFG Investments LLC now owns 12,494 shares of the specialty chemicals company’s stock valued at $147,000 after purchasing an additional 883 shares during the last quarter. State of Alaska Department of Revenue grew its stake in Chemours by 1.2% in the fourth quarter. State of Alaska Department of Revenue now owns 76,257 shares of the specialty chemicals company’s stock valued at $899,000 after purchasing an additional 932 shares during the last quarter. Finally, Man Group plc raised its holdings in Chemours by 0.4% in the second quarter. Man Group plc now owns 271,108 shares of the specialty chemicals company’s stock worth $3,104,000 after purchasing an additional 979 shares in the last quarter. Hedge funds and other institutional investors own 76.26% of the company’s stock.

Key Headlines Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Zacks published a new FY2028 EPS projection of $2.50, which suggests potential upside in longer‑term earnings expectations if Chemours executes on recovery/growth plans. MarketBeat: Zacks Research Notes
• Neutral Sentiment: Zacks continues to reference a consensus full‑year EPS figure around $2.03 (their note includes multiple scenarios), which provides a baseline for how their revisions compare to street expectations. MarketBeat: Zacks Research Notes
• Negative Sentiment: Zacks cut FY2026 EPS to $1.06 (from $1.75) and lowered FY2027 to $1.97 (from $2.30) — sizable reductions that imply weaker near‑ to medium‑term profitability than previously expected. MarketBeat: Zacks Research Notes
• Negative Sentiment: Zacks trimmed several quarterly forecasts across 2026–2027 (examples: Q1 2026 to ($0.09) from $0.20; Q2 2026 to $0.60 from $0.69; Q3 2026 to $0.42 from $0.57; Q4 2026 to $0.13 from $0.29; Q2–Q3 2027 also cut). These cuts signal expectations for weaker near‑term earnings or margin pressure that can weigh on the stock. MarketBeat: Zacks Research Notes

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.